Nanobiotix
Paris
France
205 articles about Nanobiotix
-
Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer
2/9/2022
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), today announced the publication of a peer-reviewed case study by researchers at The University of Texas MD Anderson Cancer Center in Clinical and Translational Radiation Oncology.
-
NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4
1/26/2022
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), today announced the publication of new preclinical immunotherapy data for novel, potentially solid tumor- and therapeutic combination-agnostic radioenhancer NBTXR3 in the Journal of Nanobiotechnology.
-
NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets
1/10/2022
NANOBIOTIX provided a corporate update highlighting key priorities and anticipated development milestones for 2022.
-
Clinical Catch-Up: January 3-7
1/10/2022
The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look. -
NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer
1/5/2022
NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX – the “Company”), today announced that the first patient has been enrolled in NANORAY-312, a global, open-label, two-arm, randomized, Investigator’s Choice phase III registration study that is designed to investigate the efficacy and safety of radiotherapy-activated NBTXR3.
-
Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022
1/4/2022
NANOBIOTIX announced that the Company’s leadership will participate in three upcoming, virtual investor conferences in January 2022.
-
Now, researchers are on the threshold of great changes that have the potential to transform non-curable diseases into those that can be cured.
-
NANOBIOTIX to Present at the 4th Annual Evercore ISI HealthCONx Conference
11/17/2021
NANOBIOTIX, a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced that Laurent Levy, co-founder and chief executive officer, will participate in a virtual fireside chat at the 4th annual Evercore ISI HealthCONx Conference on Thursday, December 2, 2021, at 1:00 PM EST / 7:00 PM CET.
-
NANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare Conference
11/3/2021
NANOBIOTIX today announced that Laurent Levy, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference at 3:40 PM GMT / 10:40 AM EST on Tuesday
-
NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Frail Patients With HNSCC in Phase I Expansion Evaluating Nbtxr3 as a Single Agent Activated by Radiotherapy
10/24/2021
NANOBIOTIX announced first ever survival data from its priority head and neck cancer development program at the 2021 Annual Meeting of the American Society for Radiation Oncology.
-
Nanobiotix is developing a way for its locally-injected radio enhancer NBTXR3 for solid tumors to treat metastasized cancers. Here's what you need to know about it.
-
With the 2021 American Society of Clinical Oncology Annual Meeting now in high gear, there is plenty of news. Here’s a look at just some of the most recent stories.
-
NANOBIOTIX to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
5/26/2021
NANOBIOTIX, a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced that Laurent Levy, co-founder and chief executive officer, will discuss the Company’s latest corporate and clinical developments in a fireside chat at the Jefferies Virtual Healthcare Conference on the 4th of June at 8:00 AM Eastern Time.
-
Nanobiotix Announces the Appointment of Dr. Gary Phillips as Chairman of the Nanobiotix Supervisory Board
5/25/2021
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Gary Phillips, MD, has been appointed as the new chairman of the Company’s supervisory board.
-
Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology
5/19/2021
Updated results from phase I dose expansion in head and neck cancer showed durable signs of efficacy at a median follow up of 8.1 months, with an overall objective response rate of 82.5% and a complete response rate of 62.5% Data from the expansion part of the study continue to support NBTXR3 as feasible and well-tolerated in highly vulnerable patients with high unmet needs and significant burden of disease
-
Nanobiotix to Present at the UBS Global Healthcare Virtual Conference
5/12/2021
NANOBIOTIX, a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced that Laurent Levy, chief executive officer, will present at the UBS Global Healthcare Virtual Conference on Monday, May 24, 2021 at 7:00 am Eastern Time.
-
NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumor Types and Therapeutic Combinations in China and Other Asian Markets
5/11/2021
LianBio to collaborate in the development of NBTXR3, and contribute to enrollment in five future global registrational studies across several tumor types and therapeutic combinations including immunotherapy
-
Nanobiotix Combined Shareholders Meeting to Be Held April 28, 2021
4/12/2021
Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘ Company ’’) (Paris:NANO) (NASDAQ:NBTX) , a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that its annual Combined Shareholders Meeting is to be held on April 28, 2021
-
NANOBIOTIX Reports Full Year 2020 Financial Results and Highlights Operational Progress
3/17/2021
Substantial progress in priority development pathway in head and neck cancer with clinical registration plan announced, Fast Track designation granted by US Food and Drug Administration, and new data from phase I dose expansion showing 83% objective response rate in primary lesion.
-
NANOBIOTIX and PharmaEngine Mutually Agree to Conclude Collaboration
3/4/2021
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the Company has reached an agreement with PharmaEngine, Inc. (“PharmaEngine”) to terminate the License and Collaboration agreement that the Company and PharmaEngine entered into in August 2012.